20 articles
Phase 2 trial explores whether combining oncolytic virus therapy with immunotherapy can rescue patients whose melanoma progressed on PD-1 blockade.
Engineered immune cells target CD19+ cancer cells in patients with treatment-resistant lymphoma and leukemia.
Scientists modified patients' immune cells to better recognize and attack cancer tumors expressing NY-ESO-1 protein.
Modified immune cells engineered to overcome cancer's defenses completed safety testing in lymphoma patients.
Small trial tests modified immune cells injected directly into chest cavity to fight aggressive cancer with 12-month survival rate.
Genetically modified immune cells target blood cancer that stopped responding to standard treatments in 28-patient trial.
Small trial tests innovative immune cell therapy for patients with relapsed non-Hodgkin's lymphoma who failed standard treatments.
Researchers modified children's own immune cells to fight B-cell leukemia and lymphoma when standard treatments failed.
Autologous NK cell therapy combined with immunotherapy tested in 27 patients with treatment-resistant cancers.
MD Anderson's Phase 1/2 trial explored injecting rituximab directly into spinal fluid to target CNS lymphoid malignancies.
New liquid biopsy technique identifies molecular residual disease in colorectal cancer patients to guide personalized treatment decisions.
French study explores how tiny cellular packages in blood could predict cancer recurrence and guide treatment decisions.
Engineered immune cells target liver cancer protein in phase I safety study, though trial ended early with 10 patients.
Italian researchers track genomic and cellular changes in myeloma patients to uncover why anti-CD38 treatments stop working.
Innovative immunotherapy approach converts patient tumor cells into personalized vaccines to fight aggressive brain cancer.
Phase 1 trial tests innovative immunotherapy for multiple myeloma and lymphoma patients who didn't respond to standard treatments.
Pfizer's first-in-human trial of PF-07209960, a dual-action immunotherapy fusion protein, was terminated after enrolling 37 patients.
Modified immune cells targeting GD2 protein demonstrated safety in treating aggressive childhood cancers like neuroblastoma and osteosarcoma.
Phase 1 trial evaluates PF-06863135 (elranatamab) alone and with immunomodulatory agents to find safe dosing in heavily pretreated myeloma patients.
Small trial tests innovative treatment IBI346 for blood cancer patients who didn't respond to standard therapies.
